Measles Patients May Soon Have a Treatment

In 2025, the United States reached an unfortunate milestone with a record number of measles cases, leading many patients to look for medication.

According to a press release issued today by NanoViricides, Inc., the company has made significant progress in developing a drug to combat measles.

On July 21, 2025, NanoViricides stated NV-387 showed strong antiviral effectiveness against the measles virus.

"NV-387 is on its way to become the very first drug to treat Measles," commented Anil R. Diwan, PhD, adding, "Measles cases are skyrocketing globally, and the world needs a drug."

NV-387 is a clinical-stage, broad-spectrum antiviral drug designed to act as a decoy for a cell, presenting to the virus the very features it requires for binding to the cell. Upon binding, the virus particle is destroyed, preventing infection.

While most measles cases can be prevented through vaccination, the percentage of the population that would not benefit from vaccination continues to increase due to chronic diseases and immunological deficiencies.

Thus, a treatment for measles is of paramount importance to the global health community.